Table 2.
Characteristics of the NAFLD patients according to the HSD17B13 genotype.
| Variable | HSD17B13 | ||
|---|---|---|---|
| AA n = 72 |
AG/GG n = 68 |
p-Value | |
| PNPLA3, CC/CG/GG | 15/30/27 | 15/28/25 | 0.984 |
| Sex, female | 38 (52.8%) | 31 (45.6%) | 0.404 |
| Age, years | 55 (17–81) | 54 (23–70) | 0.925 |
| BMI, kg/m2 | 27.0 (17.6–45.2) | 28.2 (17.9–34.0) | 0.809 |
| Hypertension | 31 (43.1%) | 24 (35.3%) | 0.865 |
| Diabetes | 33 (45.8%) | 23 (33.8%) | 0.866 |
| Hyperlipidemia | 45 (62.5%) | 29 (42.6%) | 0.232 |
| Albumin, g/dL | 4.4 (3.5–5.2) | 4.5 (3.8–4.8) | 0.306 |
| AST, IU/L | 50 (19–162) | 38.5 (12–64) | 0.002 |
| ALT, IU/L | 62 (21–233) | 47.5 (14–165) | 0.021 |
| GGT, IU/L | 66 (18–533) | 56.5 (14–279) | 0.316 |
| Platelet count, ×103/μL | 213 (81–420) | 237.5 (75–444) | 0.060 |
| Total cholesterol, mg/dL | 195 (95–347) | 204.5 (94–311) | 0.108 |
| TG, mg/dL | 154 (49–721) | 141 (53–739) | 0.400 |
| LDL–C, mg/dL | 113.5 (36–252) | 124 (33–219) | 0.276 |
| HDL–C, mg/dL | 49 (21–82) | 51 (30–96) | 0.191 |
| FPG, mg/dL | 112 (71–222) | 107 (77–236) | 0.854 |
| HbA1c, % | 6.0 (5.2–8.5) | 6.1 (5.0–11.2) | 0.851 |
| FIB-4 index | 1.51 (0.33–7.83) | 1.15 (0.28–7.73) | 0.033 |
| CAP, dB/m | 313 (174–400) | 304.5 (159–400) | 0.370 |
| LSM, kPa | 9.4 (3.7–29.6) | 8.1 (2.9–46.4) | 0.158 |
| Fibrosis stage (0/1/2/3/4) | 20/26/11/10/5 | 32/19/6/7/4 | 0.210 |
Abbreviations are listed in the footnote to Table 1. HSD17B13, 17–β hydroxysteroid dehydrogenase 13.